Tivozanib

Summary

Tivozanib (CHEMBL1289494) is an approved small-molecule vascular endothelial growth factor receptor antagonist (ATC L01EK03) targeting FLT1, KDR, and FLT4; indicated across 13 conditions including neoplasm and renal cell carcinoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01EK03
• Targets: 3 (FLT1, KDR, FLT4)
• Indications: 13 conditions
• Clinical trials: 36
• Chemistry: 454.9 Da · C22H19ClN4O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1289494
Name	Tivozanib
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	9911830
ChEBI	CHEBI:91327
ATC	L01EK03
Molecular formula	C22H19ClN4O5
Molecular weight	454.9
InChIKey	SPMVMDHWKHCIDT-UHFFFAOYSA-N

SMILES: CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl

IUPAC name: 1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea

ChEBI definition: A member of the class of quinolines that is 6,7-dimethoxyquinoline substituted by a 3-chloro-4-{[(5-methyl-1,2-oxazol-3-yl)carbamoyl]amino}phenoxy group at position 4. It is a potent and selective inhibitor of VEGF receptor tyrosine kinases and was previously in clinical development for the treatment of metastatic renal cell carcinoma.

Pharmacological roles (ChEBI): vascular endothelial growth factor receptor antagonist, antineoplastic agent, apoptosis inducer.

Also known as: ASP-4130, AV-951, KIL8951, Krn-951, KRN-951, Kil-8951, Tivozanib, TIVOZANIB, TIVOZANIB HCL, TIVOZANIB (AV-951), TIVOZANIB (OPHTHALMIC), OPHTHOTECH

Parent form; salt/anhydrous children: CHEMBL2105756, CHEMBL3426917, CHEMBL4784300

Patent coverage: 1,753 distinct patent families (4,455 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 4,192 (94%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
FLT1	fms related receptor tyrosine kinase 1	Inhibition	9.68	0.1%	P17948
KDR	kinase insert domain receptor	Inhibition	9.8	1.1%	P35968
FLT4	fms related receptor tyrosine kinase 4	Inhibition	9.62	0.2%	P35916

Broader ChEMBL bioactivity targets: 42 (assay-derived). Sample: Receptor-interacting serine/threonine-protein kinase 3, Tyrosine-protein kinase ABL1, Vascular endothelial growth factor receptor 1, Platelet-derived growth factor receptor beta, Mast/stem cell growth factor receptor Kit, Vascular endothelial growth factor receptor 3, Receptor-type tyrosine-protein kinase FLT3, Platelet-derived growth factor receptor alpha, Proto-oncogene tyrosine-protein kinase receptor Ret, Ephrin type-A receptor 2, Aurora kinase B, 5-hydroxytryptamine receptor 2A, Alpha-1A adrenergic receptor, Sodium-dependent dopamine transporter, cGMP-inhibited 3’,5’-cyclic phosphodiesterase 3A, Tyrosine-protein kinase Lck, Proto-oncogene tyrosine-protein kinase Src, Vascular endothelial growth factor receptor 2, 3’,5’-cyclic-AMP phosphodiesterase 4D, Ephrin type-B receptor 2.

Bioactivity

ChEMBL activities: 61 potent at pChembl ≥ 5 of 65 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
MAPK3	9.89	IC50	0.13	nM	CHEMBL_ACT_26238416
KDR	9.8	IC50	0.16	nM	CHEMBL_ACT_12138557
KDR	9.8	IC50	0.16	nM	CHEMBL_ACT_26238405
KDR	9.8	IC50	0.16	nM	CHEMBL_ACT_3595762
MAPK1	9.74	IC50	0.18	nM	CHEMBL_ACT_26238417
FLT1	9.68	IC50	0.21	nM	CHEMBL_ACT_12138558
P35969	9.68	IC50	0.21	nM	CHEMBL_ACT_26238406
FLT4	9.62	IC50	0.24	nM	CHEMBL_ACT_12138556
FLT4	9.62	IC50	0.24	nM	CHEMBL_ACT_26238407
KIT	8.79	IC50	1.63	nM	CHEMBL_ACT_26238408
PDGFRB	8.76	IC50	1.72	nM	CHEMBL_ACT_26238409
KDR	8.67	IC50	2.14	nM	CHEMBL_ACT_15249768
PDGFRA	8.65	IC50	2.26	nM	CHEMBL_ACT_15249764
PEBP1	8.52	Kd	3	nM	CHEMBL_ACT_17925316
FLT4	8.51	IC50	3.11	nM	CHEMBL_ACT_15249766
KDR	8.47	IC50	3.38	nM	CHEMBL_ACT_26150872
FLT1	8.2	IC50	6.26	nM	CHEMBL_ACT_15249770
KDR	8.19	IC50	6.5	nM	CHEMBL_ACT_26238376
KDR	8.19	Ki	6.5	nM	CHEMBL_ACT_27790679
RET	7.92	Kd	12	nM	CHEMBL_ACT_17935227
FLT4	7.82	IC50	15	nM	CHEMBL_ACT_26238377
EPHB2	7.76	IC50	17.5	nM	CHEMBL_ACT_15249762
EPHB2	7.62	IC50	24	nM	CHEMBL_ACT_26238378
FLT1	7.52	IC50	30	nM	CHEMBL_ACT_26238375
PDGFRA	7.4	IC50	40	nM	CHEMBL_ACT_26238379
PDGFRB	7.31	IC50	49	nM	CHEMBL_ACT_26238380
ABCG2	7.16	IC50	70	nM	CHEMBL_ACT_24777477
KIT	7.11	IC50	78	nM	CHEMBL_ACT_26238381
TEK	7.11	IC50	78	nM	CHEMBL_ACT_26238382
FRK	6.84	Kd	145	nM	CHEMBL_ACT_17903841
EPHA2	6.83	Kd	147	nM	CHEMBL_ACT_17899534
BCR	6.8	Kd	160	nM	CHEMBL_ACT_17884559
DDR1	6.72	Kd	190	nM	CHEMBL_ACT_17896053
ABL1	6.71	Kd	195	nM	CHEMBL_ACT_17878449
ABL2	6.52	Kd	302	nM	CHEMBL_ACT_17878735
FGFR1	6.52	IC50	299	nM	CHEMBL_ACT_26238411
EPHB4	6.51	Kd	310	nM	CHEMBL_ACT_17900802
KDR	6.47	IC50	340	nM	CHEMBL_ACT_15044437
FLT3	6.38	IC50	422	nM	CHEMBL_ACT_26238410
EPHB2	6.35	Kd	448	nM	CHEMBL_ACT_17900440
EPHB4	6.32	IC50	480	nM	CHEMBL_ACT_26238383
FGFR1	6.28	IC50	530	nM	CHEMBL_ACT_26238384
MET	6.26	IC50	550	nM	CHEMBL_ACT_26238385
DDR2	6.23	Kd	592	nM	CHEMBL_ACT_17896287
EPHA5	6.22	Kd	601	nM	CHEMBL_ACT_17899967
ABL1	6.21	IC50	620	nM	CHEMBL_ACT_26238386
PTK6	6.1	Kd	787	nM	CHEMBL_ACT_17933073
RIPK2	6.1	Kd	801	nM	CHEMBL_ACT_17935485
SRC	6.02	IC50	960	nM	CHEMBL_ACT_26238387
RIPK3	5.87	Kd	1346	nM	CHEMBL_ACT_17935722
MET	5.87	IC50	1360	nM	CHEMBL_ACT_26238412
AURKB	5.81	Kd	1562	nM	CHEMBL_ACT_17884292
LYN	5.7	Kd	2019	nM	CHEMBL_ACT_17910037
LCK	5.66	Kd	2183	nM	CHEMBL_ACT_17909495
MAP4K2	5.62	Kd	2375	nM	CHEMBL_ACT_17913628
PDGFRB	5.62	Kd	2409	nM	CHEMBL_ACT_17924682
SLC6A3	5.58	AC50	2600	nM	CHEMBL_ACT_25123713
STK10	5.33	Kd	4622	nM	CHEMBL_ACT_17940570
MET	5.27	Kd	5403	nM	CHEMBL_ACT_17919122
EPHB3	5.26	Kd	5433	nM	CHEMBL_ACT_17900587
EPHA4	5.25	Kd	5563	nM	CHEMBL_ACT_17899724

Target pathways

Aggregated over 3 target gene(s): FLT1, KDR, FLT4.

Top Reactome pathways

8 total, by targets touching each:

Pathway	Targets	Genes
VEGF binds to VEGFR leading to receptor dimerization	3	FLT1, FLT4, KDR
Neuropilin interactions with VEGF and VEGFR	2	FLT1, KDR
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	2	FLT4, KDR
Integrin cell surface interactions	1	KDR
VEGFA-VEGFR2 Pathway	1	KDR
VEGFR2 mediated cell proliferation	1	KDR
NOTCH4 Intracellular Domain Regulates Transcription	1	FLT4
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB	1	KDR

Dominant GO biological processes

GO term	Targets
cell surface receptor protein tyrosine kinase signaling pathway	3
positive regulation of cell population proliferation	3
cell migration	3
peptidyl-tyrosine phosphorylation	3
positive regulation of cell migration	3
cellular response to vascular endothelial growth factor stimulus	3
positive regulation of MAPK cascade	3
protein autophosphorylation	3
vascular endothelial growth factor receptor signaling pathway	3
angiogenesis	3
protein phosphorylation	3
vascular endothelial growth factor signaling pathway	3
sprouting angiogenesis	2
cell differentiation	2
positive regulation of angiogenesis	2

Indications & clinical

Indications

3 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
neoplasm	3	MONDO:0005070	EFO:0000616
renal cell carcinoma	3	MONDO:0005086	EFO:0000681
renal cell adenocarcinoma	3	MONDO:0005549	EFO:0005708

9 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
hepatocellular carcinoma	2	MONDO:0007256	EFO:0000182
glioblastoma	2	MONDO:0018177	EFO:0000519
soft tissue sarcoma	2	MONDO:0018078	EFO:1001968
fallopian tube neoplasm	2	MONDO:0021092	MONDO:0002158
ovarian cancer	2	MONDO:0008170	MONDO:0008170
colorectal neoplasm	2	MONDO:0005335	MONDO:0005575
non-small cell lung carcinoma	1	MONDO:0005233	EFO:0003060
breast neoplasm	1	MONDO:0021100	MONDO:0007254
cholangiocarcinoma	1	MONDO:0019087	EFO:0005221

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 36.

Phase distribution

Phase	Trials
PHASE2	13
PHASE1	10
PHASE1/PHASE2	7
PHASE3	4
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06661720	PHASE3	RECRUITING	Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
NCT01030783	PHASE3	COMPLETED	A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma
NCT01076010	PHASE3	COMPLETED	An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).
NCT04987203	PHASE3	COMPLETED	Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
NCT04645160	PHASE1/PHASE2	RECRUITING	Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
NCT06053658	PHASE2	RECRUITING	Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
NCT07218692	PHASE2	NOT_YET_RECRUITING	RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
NCT00502307	PHASE2	COMPLETED	A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma
NCT01058655	PHASE1/PHASE2	COMPLETED	RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
NCT01297244	PHASE2	COMPLETED	A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma
NCT01478594	PHASE2	COMPLETED	A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
NCT01673386	PHASE2	TERMINATED	A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC
NCT01728181	PHASE1/PHASE2	WITHDRAWN	A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation
NCT01782313	PHASE2	COMPLETED	A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
NCT01807156	PHASE2	TERMINATED	Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
NCT01834183	PHASE2	WITHDRAWN	Tivozanib + Gemcitabine in Metastatic RCC
NCT01835223	PHASE1/PHASE2	COMPLETED	Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery
NCT01846871	PHASE2	COMPLETED	Tivozanib for Recurrent Glioblastoma
NCT01853644	PHASE2	COMPLETED	Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT01885949	PHASE2	TERMINATED	Tivozanib + Enzalutamide in Adv Prostate Cancer
NCT01972516	PHASE2	TERMINATED	Tivozanib As Maintenance Therapy In GYN
NCT03136627	PHASE1/PHASE2	COMPLETED	Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC
NCT03970616	PHASE1/PHASE2	TERMINATED	A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
NCT05000294	PHASE1/PHASE2	SUSPENDED	Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
NCT00563147	PHASE1	COMPLETED	A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma
NCT00660153	PHASE1	COMPLETED	Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers
NCT00717340	PHASE1	COMPLETED	A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer
NCT00826878	PHASE1	COMPLETED	An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)
NCT00970411	PHASE1	COMPLETED	Study of KRN951 in Patients With Solid Tumors
NCT01210846	PHASE1	COMPLETED	A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors
NCT01306630	PHASE1	COMPLETED	A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
NCT01316848	PHASE1	COMPLETED	A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Tivozanib (AV-951) in Healthy Subjects
NCT01363778	PHASE1	COMPLETED	A Phase 1 Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics of Tivozanib in Healthy Subjects
NCT01363804	PHASE1	COMPLETED	A Phase 1 Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Tivozanib in Healthy Subjects
NCT01369433	Not specified	TERMINATED	A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
NCT01769885	Not specified	WITHDRAWN	Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

174 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	FLT1, FLT4, KDR
Gefitinib	ChEMBL + PubChem	Phase 4 (approved)	FLT1, FLT4, KDR
PAZOPANIB	ChEMBL + PubChem	Phase 4 (approved)	FLT1, FLT4, KDR
REGORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	FLT1, FLT4, KDR
AXITINIB	ChEMBL	Phase 4 (approved)	FLT1, FLT4, KDR
CABOZANTINIB	ChEMBL	Phase 4 (approved)	FLT1, FLT4, KDR
ENTRECTINIB	ChEMBL	Phase 4 (approved)	FLT1, FLT4, KDR
ERLOTINIB	ChEMBL	Phase 4 (approved)	FLT1, FLT4, KDR
FEDRATINIB	ChEMBL	Phase 4 (approved)	FLT1, FLT4, KDR
FRUQUINTINIB	ChEMBL	Phase 4 (approved)	FLT1, FLT4, KDR
INFIGRATINIB	ChEMBL	Phase 4 (approved)	FLT1, FLT4, KDR
LENVATINIB	ChEMBL	Phase 4 (approved)	FLT1, FLT4, KDR
MIDOSTAURIN	ChEMBL	Phase 4 (approved)	FLT1, FLT4, KDR
NINTEDANIB	ChEMBL	Phase 4 (approved)	FLT1, FLT4, KDR
NINTEDANIB ESYLATE	ChEMBL	Phase 4 (approved)	FLT1, FLT4, KDR
QUIZARTINIB	ChEMBL	Phase 4 (approved)	FLT1, FLT4, KDR
SORAFENIB	ChEMBL	Phase 4 (approved)	FLT1, FLT4, KDR
SUNITINIB	ChEMBL	Phase 4 (approved)	FLT1, FLT4, KDR
VANDETANIB	ChEMBL	Phase 4 (approved)	FLT1, FLT4, KDR
BRIVANIB	ChEMBL	Phase 3	FLT1, FLT4, KDR
CEDIRANIB	ChEMBL	Phase 3	FLT1, FLT4, KDR
CEP-1347	ChEMBL	Phase 3	FLT1, FLT4, KDR
DOVITINIB	ChEMBL	Phase 3	FLT1, FLT4, KDR
LESTAURTINIB	ChEMBL	Phase 3	FLT1, FLT4, KDR
LINIFANIB	ChEMBL	Phase 3	FLT1, FLT4, KDR
MOTESANIB	ChEMBL	Phase 3	FLT1, FLT4, KDR
SEMAXANIB	ChEMBL	Phase 3	FLT1, FLT4, KDR
SURUFATINIB	ChEMBL	Phase 3	FLT1, FLT4, KDR
VATALANIB	ChEMBL	Phase 3	FLT1, FLT4, KDR
AT-9283	ChEMBL	Phase 2	FLT1, FLT4, KDR
BFH-772	ChEMBL	Phase 2	FLT1, FLT4, KDR
CENISERTIB	ChEMBL	Phase 2	FLT1, FLT4, KDR
DEFOSBARASERTIB	ChEMBL	Phase 2	FLT1, FLT4, KDR
DORAMAPIMOD	ChEMBL	Phase 2	FLT1, FLT4, KDR
FORETINIB	ChEMBL	Phase 2	FLT1, FLT4, KDR
ILORASERTIB	ChEMBL	Phase 2	FLT1, FLT4, KDR
LUCITANIB	ChEMBL	Phase 2	FLT1, FLT4, KDR
MK-2461	ChEMBL	Phase 2	FLT1, FLT4, KDR
OSI-632	ChEMBL	Phase 2	FLT1, FLT4, KDR
R-406	ChEMBL	Phase 2	FLT1, FLT4, KDR
RAF-265	ChEMBL	Phase 2	FLT1, FLT4, KDR
REBASTINIB	ChEMBL	Phase 2	FLT1, FLT4, KDR
SU-014813	ChEMBL	Phase 2	FLT1, FLT4, KDR
TANDUTINIB	ChEMBL	Phase 2	FLT1, FLT4, KDR
TOZASERTIB	ChEMBL	Phase 2	FLT1, FLT4, KDR
Afatinib	PubChem	Approved	FLT1, FLT4, KDR
Selumetinib	PubChem	Approved	FLT1, FLT4, KDR
BRIGATINIB	ChEMBL	Phase 4 (approved)	FLT4, KDR
DASATINIB	ChEMBL	Phase 4 (approved)	FLT1, KDR
FILGOTINIB	ChEMBL	Phase 4 (approved)	FLT1, FLT4
PEXIDARTINIB	ChEMBL	Phase 4 (approved)	FLT1, KDR
PONATINIB	ChEMBL	Phase 4 (approved)	FLT1, KDR
ALISERTIB	ChEMBL	Phase 3	FLT1, KDR
CANERTINIB	ChEMBL	Phase 3	FLT1, KDR
DEFACTINIB	ChEMBL	Phase 3	FLT1, KDR
ORANTINIB	ChEMBL	Phase 3	FLT1, KDR
AEE-788	ChEMBL	Phase 2	FLT1, KDR
CEP-11981	ChEMBL	Phase 2	FLT1, KDR
CEP-32496	ChEMBL	Phase 2	FLT1, KDR
DANUSERTIB	ChEMBL	Phase 2	FLT4, KDR
ELLAGIC ACID	ChEMBL	Phase 2	FLT4, KDR
SOTRASTAURIN	ChEMBL	Phase 2	FLT4, KDR
TAK-715	ChEMBL	Phase 2	FLT4, KDR
TELATINIB	ChEMBL	Phase 2	FLT4, KDR
Idelalisib	PubChem	Approved	FLT1, FLT4
GENTIAN VIOLET	ChEMBL + PubChem	Phase 4 (approved)	KDR
ABEMACICLIB	ChEMBL	Phase 4 (approved)	KDR
ABROCITINIB	ChEMBL	Phase 4 (approved)	KDR
ACALABRUTINIB	ChEMBL	Phase 4 (approved)	KDR
ALECTINIB	ChEMBL	Phase 4 (approved)	KDR
AUROTHIOGLUCOSE	ChEMBL	Phase 4 (approved)	KDR
CABOZANTINIB S-MALATE	ChEMBL	Phase 4 (approved)	KDR
CERITINIB	ChEMBL	Phase 4 (approved)	KDR
ENASIDENIB	ChEMBL	Phase 4 (approved)	KDR
ERDAFITINIB	ChEMBL	Phase 4 (approved)	KDR
ESTRAMUSTINE	ChEMBL	Phase 4 (approved)	KDR
FOSTAMATINIB DISODIUM	ChEMBL	Phase 4 (approved)	KDR
FUTIBATINIB	ChEMBL	Phase 4 (approved)	KDR
GLAFENINE	ChEMBL	Phase 4 (approved)	KDR
HEXACHLOROPHENE	ChEMBL	Phase 4 (approved)	KDR
IBRUTINIB	ChEMBL	Phase 4 (approved)	KDR
IMATINIB	ChEMBL	Phase 4 (approved)	KDR
INDIGOTINDISULFONATE	ChEMBL	Phase 4 (approved)	KDR
ISOXICAM	ChEMBL	Phase 4 (approved)	KDR
MEBENDAZOLE	ChEMBL	Phase 4 (approved)	KDR
MESALAMINE	ChEMBL	Phase 4 (approved)	KDR
NERATINIB	ChEMBL	Phase 4 (approved)	KDR
NICLOSAMIDE	ChEMBL	Phase 4 (approved)	KDR
NOVOBIOCIN	ChEMBL	Phase 4 (approved)	KDR
OLMUTINIB	ChEMBL	Phase 4 (approved)	KDR
OLSALAZINE	ChEMBL	Phase 4 (approved)	KDR
OSIMERTINIB	ChEMBL	Phase 4 (approved)	KDR
PHENYL AMINOSALICYLATE	ChEMBL	Phase 4 (approved)	KDR
PIPERAZINE	ChEMBL	Phase 4 (approved)	KDR
SELPERCATINIB	ChEMBL	Phase 4 (approved)	KDR
SORAFENIB TOSYLATE	ChEMBL	Phase 4 (approved)	KDR
STIRIPENTOL	ChEMBL	Phase 4 (approved)	KDR
SUNITINIB MALATE	ChEMBL	Phase 4 (approved)	KDR
TOFACITINIB	ChEMBL	Phase 4 (approved)	KDR
UPADACITINIB	ChEMBL	Phase 4 (approved)	KDR